PharmaMar rated "Excellent" in the category of R&D

companies under the PROFARMA programme

PharmaMar, a Grupo Zeltia subsidiary specialised in developing marine-based anti-tumour drugs, received the highest possible score from the Spanish Ministry of Industry, Energy and Tourism

The score is based on industrial, economic and R&D parameters

Madrid, 20 February 2013: PharmaMar S.A. (Grupo Zeltia, ZEL.MC), a leader in the development of marine-based anti-tumour drugs, has been rated "Excellent" by the Committee for the Programme to Promote Scientific Research and Technological Development and Innovation in the Spanish pharmaceutical industry (PROFARMA).

The new PROFARMA further expands the projects undertaken in former programmes and, having consideration for the industrial situation in Spain, seeks to favour a framework of stability and uncertainty for the pharmaceutical industry in order to foster investment.

PharmaMar, which obtained an "Excellent" rating in the last eleven editions, is included in the programme's Group A, i.e. "Companies with significant research activity and their own production plant or R&D facility (basic or pre-clinical)".

The company has a comprehensive cancer research programme, which includes drug discovery, preclinical research and clinical development, through to production and commercialisation. The company's headquarters, laboratories and production plant are in Colmenar Viejo (Madrid).

About PharmaMar
PharmaMar is a biopharmaceutical subsidiary of Grupo Zeltia; it is a world leader in discovering, developing and selling marine-based drugs to treat cancer. Yondelis® is Spain's first antitumour drug. Yondelis® is currently approved for soft tissue sarcoma (STS) in 42 countries outside the EEA, and for platinum-sensitive relapsed ovarian cancer (ROC) in 31 of those countries plus Brazil. Yondelis® is approved for STS and platinum-sensitive ROC in all 30 countries of the EEA. Yondelis® is also undergoing Phase II trials on breast and paediatric cancers. PharmaMar has four other compounds in clinical development: Aplidin®, Zalypsis®, PM01183 and PM060184. PharmaMar also has a rich pipeline of pre-clinical candidates and a major R&D programme.

About Zeltia
Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine- based drugs for use in oncology. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.
Important note
PharmaMar, which is headquartered in Madrid (Spain), is a subsidiary of Grupo Zeltia (Spanish stock exchange: ZEL), which has been listed on the Spanish Stock Exchange since 1963 and on Spain's Electronic Market since 1998. This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

For more information +34 91 444 4500


This note is also available on the PharmaMar web site: www.pharmamar.comand at Zeltia's website:
www.zeltia.com

distributed by